帕博利珠单抗治疗复发或难治性原发纵隔大B细胞淋巴瘤
KEYNOTE-013(IB期)和KEYNOTE-170(II期)研究评估帕博利珠单抗用于复发或难治性原发纵隔大B细胞淋巴瘤(rrPMBCL)成人患者,最长治疗2年。KEYNOTE-013中21例客观缓解率48%(完全缓解7例,33%),KEYNOTE-170中53例客观缓解率45%(完全缓解7例,13%);中位缓解持续时间均未达到,完全缓解者均未进展,治疗相关不良事件发生率分别为24%和23%,无治疗相关死亡。
要点
- 帕博利珠单抗在rrPMBCL中客观缓解率48%(KEYNOTE-013)和45%(KEYNOTE-170)。
- 完全缓解者均未出现进展,中位缓解持续时间未达到。
- 治疗相关不良事件发生率约23%–24%,无治疗相关死亡。
核心结论
- 帕博利珠单抗在rrPMBCL患者中与高缓解率、持久活性和可控的安全性相关。
研究设计与样本
- IB期KEYNOTE-013(NCT01953692)纳入21例rrPMBCL成人患者,接受帕博利珠单抗最长2年或至疾病进展/不可接受毒性。
- II期KEYNOTE-170(NCT02576990)纳入53例rrPMBCL成人患者,接受帕博利珠单抗最长2年或至疾病进展/不可接受毒性。
- KEYNOTE-013主要终点为安全性和客观缓解率,KEYNOTE-170主要终点为客观缓解率。
主要发现
- KEYNOTE-013中21例患者客观缓解率48%(完全缓解7例,33%)。
- KEYNOTE-170中53例患者客观缓解率45%(完全缓解7例,13%)。
- KEYNOTE-013中位随访29.1个月、KEYNOTE-170中位随访12.5个月,两项研究中位缓解持续时间均未达到。
- 完全缓解患者均未出现进展,包括2例完全缓解后停药至少1年者。
- 治疗相关不良事件发生率KEYNOTE-013为24%、KEYNOTE-170为23%,无治疗相关死亡。
关键数值与推荐
- 在42例可评估患者中,9p24基因异常程度与PD-L1表达相关。
- PD-L1表达与无进展生存期显著相关。
临床怎么用
- 帕博利珠单抗可作为复发或难治性原发纵隔大B细胞淋巴瘤的治疗选择之一。
- 治疗最长持续2年或至疾病进展/不可接受毒性。
- 完全缓解患者可能获得持久获益,包括停药后持续缓解。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Patients with relapsed or refractory primary mediastinal large B-cell lymphoma (rrPMBCL) have a poor prognosis, and their treatment represents an urgent and unmet need. Because PMBCL is associated with genetic aberrations at 9p24 and overexpression of programmed cell death-1 (PD-1) ligands (PD-L1), it is hypothesized to be susceptible to PD-1 blockade. METHODS: In the phase IB KEYNOTE-013 (ClinicalTrials.gov identifier: NCT01953692) and phase II KEYNOTE-170 (ClinicalTrials.gov identifier: NCT02576990) studies, adults with rrPMBCL received pembrolizumab for up to 2 years or until disease progression or unacceptable toxicity. The primary end points were safety and objective response rate in KEYNOTE-013 and objective response rate in KEYNOTE-170. Secondary end points included duration of response, progression-free survival, overall survival, and safety. Exploratory end points included association between biomarkers and pembrolizumab activity. RESULTS: The objective response rate was 48% (7 complete responses; 33%) among 21 patients in KEYNOTE-013 and 45% (7 complete responses; 13%) among 53 patients in KEYNOTE-170. After a median follow-up time of 29.1 months in KEYNOTE-013 and 12.5 months in KEYNOTE-170, the median duration of response was not reached in either study. No patient with complete response experienced progression, including 2 patients with complete response for at least 1 year off therapy. Treatment-related adverse events occurred in 24% of patients in KEYNOTE-013 and 23% of patients in KEYNOTE-170. There were no treatment-related deaths. Among 42 evaluable patients, the magnitude of the 9p24 gene abnormality was associated with PD-L1 expression, which was itself significantly associated with progression-free survival. CONCLUSION: Pembrolizumab is associated with high response rate, durable activity, and a manageable safety profile in patients with rrPMBCL.
引用
- Armand P, Rodig S, Melnichenko V, et al. Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma. J Clin Oncol. 2019. PMID: 31609651. doi:10.1200/JCO.19.01389
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。